This study explores the therapeutic potential of Mazindol ER, a triple monoamine reuptake inhibitor with additional activity on 5-HT1A, MOP, and OX2R receptors, for fentanyl dependence. Preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback